Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
Provided By GlobeNewswire
Last update: Mar 20, 2025
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital
Read more at globenewswire.com3.48
+0.19 (+5.78%)
Find more stocks in the Stock Screener
ELDN Latest News and Analysis
